Costello Asset Management INC Grows Stock Position in Eli Lilly and Company $LLY

Key Points

• Costello Asset Management INC increased its stake in Eli Lilly by 14.7% during the second quarter, now owning 9,035 shares valued at approximately $7 million.
• Multiple institutional investors have significantly increased their holdings in Eli Lilly, with PNC Financial Services Group boosting its position by 97.5% in the first quarter.
• Eli Lilly's stock recently opened at $833.08 and had a strong earnings report with a quarterly EPS of $6.31, surpassing the consensus estimate.

Costello Asset Management INC raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 14.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,035 shares of the company's stock after buying an additional 1,156 shares during the period. Eli Lilly and Company comprises about 2.6% of Costello Asset Management INC's portfolio, making the stock its 8th biggest position. Costello Asset Management INC's holdings in Eli Lilly and Company were worth $7,043,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in LLY. PNC Financial Services Group Inc. boosted its position in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares in the last quarter. Nuveen LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at about $4,613,912,000. Vanguard Group Inc. boosted its position in shares of Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares in the last quarter. Cohen Investment Advisors LLC boosted its position in shares of Eli Lilly and Company by 7,975.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock valued at $647,225,000 after purchasing an additional 773,947 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company's stock valued at $1,154,508,000 after purchasing an additional 765,010 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. HSBC upped their target price on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Guggenheim upped their price target on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a "buy" rating in a research note on Wednesday. Daiwa America downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Finally, Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $948.56.

Insider Transactions at Eli Lilly and Company

In related news, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Down 2.6%

LLY stock opened at $833.08 on Friday. The stock's 50 day simple moving average is $742.42 and its 200 day simple moving average is $766.36. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market cap of $788.47 billion, a P/E ratio of 54.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.